Tasisulam

 CAS No.: 519055-62-0  Cat No.: BP-900078  Purity: >98% 4.5  

Tasisulam is a potent molecular glue that facilitates targeted protein degradation, specifically designed to modulate the cellular protein landscape. This compound targets the E3 ubiquitin ligase complex, binding to a distinct site on the ligase, thereby promoting the ubiquitination and subsequent proteasomal degradation of target proteins. Tasisulam's unique molecular structure allows it to act as a bridge between the E3 ligase and the substrate protein, effectively tagging the latter for degradation. The primary mechanism of Tasisulam involves the recruitment of endogenous cellular machinery to eliminate proteins that are otherwise difficult to target with traditional small molecules. This product is invaluable in research applications focused on elucidating the pathways of protein homeostasis and the development of novel therapeutic strategies. Tasisulam's role in targeted degradation studies offers a transformative approach to understanding disease mechanisms and the exploration of new drug discovery paradigms, providing researchers with a powerful tool to manipulate protein levels within cells.

Tasisulam

Structure of 519055-62-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Molecular Glue
Molecular Formula
C11H6BrCl2NO3S2
Molecular Weight
415.11
Appearance
Solid

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
>98%
Solubility
≥ 20.3mg/mL in DMSO
Appearance
Solid
Storage
Store at -20°C
IUPACName
N-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide
Synonyms
LY 573636; LY573636; N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide
InChI Key
WWONFUQGBVOKOF-UHFFFAOYSA-N
InChI
InChI=1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)
SMILES
C1=CC(=C(C=C1Cl)Cl)C(=O)NS(=O)(=O)C2=CC=C(S2)Br
Mechanism

E3 Ligase: Tasisulam does not act as a classical molecular glue recruiting E3 ligases such as CRBN, VHL, IAP, or MDM2. Its activity involves modulation of protein networks that can indirectly influence ubiquitin ligase function and protein stability within the cell.

Target Protein: Tasisulam primarily targets proteins involved in cell cycle regulation and apoptosis, including factors that control mitotic progression. These interactions alter protein turnover indirectly rather than through direct recruitment for degradation.

Degradation Mechanism: Tasisulam mediates protein turnover indirectly by affecting cellular pathways that govern ubiquitin-proteasome–dependent degradation. Targeted proteins may accumulate or be degraded via the 26S proteasome as a consequence of altered signaling, without direct engagement of lysosomal degradation pathways.

Applications

• Molecular Glue for Protein Interaction Modulation: Tasisulam serves as a molecular glue by facilitating the interaction between specific proteins, leading to their ubiquitination and subsequent degradation. This mechanism offers researchers a novel approach to modulate protein function and study the dynamics of protein interactions within cellular environments.

• Targeted Protein Degradation Studies: Utilizing Tasisulam in targeted degradation studies allows scientists to selectively degrade proteins of interest, providing insights into their biological roles. This application is crucial for understanding protein function and developing strategies for therapeutic intervention in diseases where protein dysregulation is implicated.

• Enhancing Proteolysis Research: Tasisulam acts as a catalyst in proteolysis research by promoting the degradation of target proteins. Researchers can employ this compound to explore the intricacies of the ubiquitin-proteasome system, facilitating the discovery of new molecular pathways and potential drug targets.

• Investigating Protein Homeostasis: By using Tasisulam, researchers can delve into the mechanisms of protein homeostasis and its impact on cellular health. This application is vital for examining how cells maintain protein equilibrium and the consequences of its disruption in pathological conditions.

1.Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.
Meier T1, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Evans G, Credille K, Ballard D, Huber L, Capen A, Chedid M, Ilaria R Jr, Smith MC, Stancato L. Mol Cancer Ther. 2011 Nov;10(11):2168-78. doi: 10.1158/1535-7163.MCT-11-0323. Epub 2011 Sep 8.
LY573636-sodium (tasisulam) is a small molecule antitumor agent with a novel mechanism of action currently being investigated in a variety of human cancers. In vitro, tasisulam induced apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Using high content cellular imaging and subpopulation analysis of a wide range of in vitro and in vivo cancer models, tasisulam increased the proportion of cells with 4N DNA content and phospho-histone H3 expression, leading to G(2)-M accumulation and subsequent apoptosis. Tasisulam also blocked VEGF, epidermal growth factor, and fibroblast growth factor-induced endothelial cell cord formation but did not block acute growth factor receptor signaling (unlike sunitinib, which blocks VEGF-driven angiogenesis at the receptor kinase level) or induce apoptosis in primary endothelial cells. Importantly, in vivo phenocopying of in vitro effects were observed in multiple human tumor xenografts.
2.A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.
Fujiwara Y1, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R Jr, Kellie Turner P, Funai J, Maeda K, Minami H. Cancer Chemother Pharmacol. 2013 Apr;71(4):991-8. doi: 10.1007/s00280-013-2092-2. Epub 2013 Feb 1.
PURPOSE: This phase I study was designed to determine the maximum tolerated dose (MTD) and the dose to be recommended for a future phase II study of tasisulam sodium in Japanese patients with advanced, refractory solid tumors. Safety, pharmacokinetics and preliminary anti-tumor activities were assessed. Due to high-affinity albumin binding, an albumin-tailored dose to reduce the variability in tasisulam exposure was also studied.
3.A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
Simon GR1, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-41. doi: 10.1007/s00280-011-1593-0. Epub 2011 Mar 23.
PURPOSE: This phase I study was carried out to determine the phase II recommended dose of tasisulam sodium (hereafter, tasisulam), a novel anticancer agent with a unique mechanism of action.
4.A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O1, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ. Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26.
BACKGROUND: Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.
ConcentrationVolumeMass1 mg5 mg10 mg
1 mM2.4090 mL12.0450 mL24.0900 mL
5 mM0.4818 mL2.4090 mL4.8180 mL
10 mM0.2409 mL1.2045 mL2.4090 mL
50 mM0.0482 mL0.2409 mL0.4818 mL

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
Germany
Inquiry Basket